Obagi Medical Products, Inc. (Nasdaq:OMPI) reported financial results for the second quarter and six months ended June 30, 2011. Net sales for the second quarter of 2011 were equal to the second quarter of 2010 at $28.9 million. Second quarter 2011 sales were impacted by lower shipments into Texas due to regulatory agencies' attempting to impose restrictions on certain products as well as lower royalties from the Company's Japanese partner. For the second quarter 2011, net income was $2.9 million, or $0.16 per diluted share, compared with $3.1 million, or $0.14 per diluted share, in the second quarter of 2010. On a non-GAAP basis, excluding Zein Obagi legal and related costs from both this year and last, net income was $3.4 million, or $0.18 per diluted share, compared with net income of $3.8 million, or $0.17 per diluted share, a year ago.

Read full article:http://bestotc.com/17748/stock-alerts/ompi-clno-call-mndo-sgi-stocks-report-by-bestotccom/